News Archive
- FoRx Therapeutics Announces Development Candidate Nomination of Potential Best-in-Class PARG Inhibitor FORX-428
- FoRx Therapeutics AG appoints Tarig Bashir as Chief Executive Officer
- FoRx Therapeutics AG appoints Ulrich Lücking as Head of Chemistry
-
FoRx Therapeutics AG Raises EUR 10 Million Seed Round
First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer